Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Occupational eczema].

J M Lachapelle1

  • 1Unité de dermato-allergologie et dermato-immunologie de l'Université Catholique de Louvain 30, Clos Chapelle-aux-Champs UCL 3033, B-1200 Bruxelles.

La Revue Du Praticien
|January 5, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Practical Epidemiology.

Acta clinica Belgica·2016
Same author

[Dermatoporosis, a vintage for atrophoderma and transparent skin].

Revue medicale de Liege·2014
Same author

Embryotoxicity of human sera from patients treated with isotretinoin.

Toxicology in vitro : an international journal published in association with BIBRA·2010
Same author

Desloratadine 5 mg once daily improves the quality of life of patients with chronic idiopathic urticaria.

Journal of the European Academy of Dermatology and Venereology : JEADV·2006
Same author

Routine patch testing with frullanolide mix: an European Environmental and Contact Dermatitis Research Group multicentre study.

Contact dermatitis·2003
Same author

[Acquired ichthyosis disclosing Hodgkin's disease. Simultaneous recurrence].

Presse medicale (Paris, France : 1983)·2002
Same journal

[Prolonged fever].

La Revue du praticien·2026
Same journal

[Lower gastrointestinal bleeding].

La Revue du praticien·2026
Same journal

[Management of antiplatelet agents and oral anticoagulants in cases of gastrointestinal bleeding].

La Revue du praticien·2026
Same journal

[A history of child abuse intervention in the West].

La Revue du praticien·2026
Same journal

[Agranulocytose médicamenteuse].

La Revue du praticien·2026
Same journal

[Patient education in heart failure].

La Revue du praticien·2026
See all related articles

Occupational allergic contact dermatitis cases are decreasing, but new allergens like MCI/MI and acrylates are emerging. Prevention strategies for allergic contact dermatitis must be multidisciplinary, encompassing primary, secondary, and tertiary approaches.

Area of Science:

  • Dermatology
  • Occupational Health
  • Toxicology

Context:

  • While occupational allergic contact dermatitis (OACD) cases, such as those from cement chromates, are declining, new environmental haptens are emerging due to industrial advancements.
  • Examples of new haptens include methylchloroisothiazolinone/methylisothiazolinone (MCI/MI) in paints, acrylates, methacrylates, glutaraldehyde, propacetamol, and antibiotics used in healthcare settings.
  • A novel clinical condition, protein contact dermatitis, has been identified.

Purpose:

  • To analyze the evolving landscape of occupational allergic contact dermatitis, highlighting decreasing prevalence of some allergens and the emergence of new ones.
  • To underscore the importance of a comprehensive, multidisciplinary approach to preventing OACD.
  • To introduce protein contact dermatitis as a newly characterized clinical entity.

Related Experiment Videos

Summary:

  • The prevalence of occupational allergic contact dermatitis (OACD) linked to substances like cement chromates is decreasing.
  • New haptens, including methylchloroisothiazolinone/methylisothiazolinone (MCI/MI), acrylates, methacrylates, glutaraldehyde, propacetamol, and antibiotics, are increasingly identified in occupational and healthcare environments.
  • Protein contact dermatitis represents a new clinical entity within this field.

Impact:

  • Highlights the dynamic nature of OACD, necessitating continuous surveillance for novel allergens.
  • Emphasizes the need for integrated prevention strategies (primary, secondary, tertiary) to manage OACD effectively.
  • Informs healthcare professionals and industry stakeholders about emerging occupational dermatological risks and the importance of updated prevention protocols.